← back to search

Ning Liao

Shanghai Medical College of Fudan University · CN
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research focused on Breast cancer and Oncology, with related work in Clinical Oncology, Cancer, DNA sequencing. Notable publications include 'JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer', 'CACA Guidelines for Holistic Integrative Management of Breast Cancer', and 'Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)'.
h-index
citations
313
works
13
NIH funding
primary concept
email

Recent publications

A radiogenomic multimodal and whole-transcriptome sequencing for preoperative prediction of axillary lymph node metastasis and drug therapeutic response in breast cancer: a retrospective, machine learning and international multicohort study
International Journal of Surgery 2024cited by 25position: lastdoi
Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
Nature Communications 2024cited by 25position: middledoi
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
Journal of Clinical Oncology 2024cited by 11position: middledoi
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)
European Journal of Cancer 2023cited by 11position: middledoi
Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
Journal of the National Cancer Center 2023cited by 5position: middledoi
CACA Guidelines for Holistic Integrative Management of Breast Cancer
Holistic Integrative Oncology 2022cited by 57position: middledoi
Using an Improved Residual Network to Identify PIK3CA Mutation Status in Breast Cancer on Ultrasound Image
Frontiers in Oncology 2022cited by 10position: middledoi
235P Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2- advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study
Annals of Oncology 2021cited by 2position: middledoi
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
Cancer 2020cited by 36position: middledoi
Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)
Translational Breast Cancer Research 2020cited by 27position: middledoi
JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
Aging 2019cited by 70position: lastdoi
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology
Cancer Biology and Medicine 2019cited by 26position: middledoi
Multicenter cross‑sectional screening of the BRCA gene for Chinese high hereditary risk breast cancer populations
Oncology Letters 2018cited by 8position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Quchang Ouyang · Central South University2 papers (2021–2023)Jianguo Lai · Case Western Reserve University2 papers (2019–2024)Jiayu Wang · Nanjing University of Chinese Medicine2 papers (2023–2023)Liang Huang · Nanchang University1 papers (2024–2024)Shusen Wang · Nanjing Medical University1 papers (2024–2024)Xiaojia Wang · Sichuan University1 papers (2023–2023)Jifeng Feng · Zhejiang Cancer Hospital1 papers (2023–2023)Zhimin Shao · Shanghai Medical College of Fudan University1 papers (2023–2023)Qiang Sun · University of Toronto1 papers (2023–2023) · 1 papers (2023–2023)Zijun Chen · Xiamen University1 papers (2024–2024)Chao Zhu · First Affiliated Hospital of Jiangxi Medical College1 papers (2024–2024)Hongjian Yang · Sun Yat-sen University Cancer Center1 papers (2024–2024)Xichun Hu · Shanghai Medical College of Fudan University1 papers (2023–2023) · 1 papers (2024–2024) · 1 papers (2023–2023)Yan Xue · Nantong University1 papers (2023–2023)Danian Dai · Guangdong Academy of Medical Sciences1 papers (2019–2019) · 1 papers (2021–2021)Tie Sun · Nanchang University1 papers (2021–2021)